Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays:The Two-Year Bioassay Is No Longer Necessary

Toxicologic Pathology

Volumn 38, Issue 3, 2010, Pages 487-501

  Cohen, Samuel M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cytotoxicity; estrogen; genotoxicity; mitogenesis; phenobarbital; PPAR agonists; regeneration

Indexed keywords

CARCINOGEN; CHEMICAL COMPOUND; CHLOROFORM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

BIOASSAY; CANCER RISK; CARCINOGEN TESTING; CARCINOGENESIS; CARCINOGENICITY; CYTOMEGALY; DNA DAMAGE; DNA REPLICATION; HUMAN; LABELING INDEX; LIVER HYPERTROPHY; LIVER NECROSIS; LIVER TUMOR; LIVER WEIGHT; NONHUMAN; NOTE; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RODENT; SCREENING; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; RODENTIA; TIME;

RODENTIA;

EID: 77952478228     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310363813     Document Type: Review

References (110)

1. Allen D. G. Pearse G. Haseman J. K. Maronpot R. R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol 32, 393–401.
2. Ames B. N. Gold L. S. (1990). Chemical carcinogenesis: Too many rodent carcinogens. Proc Natl Acad Sci 87, 7772–76.
3. Andersen M. Brusick D. Cohen S. Dragan Y. Frederick C. Goodman J. I. Hard G. Meek B. O’Flaherty E. J. (1998). U.S. Environmental Protection Agency’s revised cancer guidelines for carcinogen risk assessment. Toxicol Appl Pharmacol 153, 133–36.
4. Andersen M. E. Meek M. E. Boorman G. A. Brusick D. J. Cohen S. M. Dragan Y. P. Frederick C. B. Goodman J. I. Hard G. C. O’Flaherty E. J. Robinson D. E. (2000). Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds. Toxicol Sci 53, 159–72.
5. Bancroft J. Stevens A. (1982). Theory and Practice of Histological Techniques. 2nd ed. Churchill Livingston, Edinburgh, UK.
6. Bonovas S. Filioussi K. Tsavaris N. Sitaras N. M. (2006). Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24, 4808–17.
7. Boobis A. R. Cohen S. M. Dellarco V. McGregor D. Meek M. E. Vickers C. Willcocks D. Farland W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36, 781–92.
8. Boobis A. R. Doe J. E. Heinrich-Hirsch B. Meek M. E. Munn S. Ruchirawat M. Schlatter J. Seed J. Vickers C. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38, 87–96.
9. G.G.P., Box, Robustness in the strategy of scientific model building, In Robustness in Statistics, Launer, R. L., Wilkinson, G. N., Academic Press, New York, (1979), 201-235
10. Browning D. R. Martin R. M. (2007). Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 120, 833–43.
11. Chlorine Chemistry Council v. EPA, 2000WL 301187, 206F. 3d 1285, D.C. Circuit Court of Appeals (2000).
12. Cohen S. (2008). Thresholds in genotoxicity and carcinogenicity: Urinary bladder carcinogenesis. Genes and Environ 30, 132–38.
13. Cohen S. M. (1998a). Cell proliferation and carcinogenesis. Drug Metab Rev 30, 339–57.
14. Cohen S. M. (1998b). Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. Int J Toxicol 17, 129–42.
15. Cohen S. M. (2004). Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci 80, 225–9.
16. Cohen S. M. Ellwein L. B. (1990a). Cell proliferation in carcinogenesis. Science 249, 1007–11.
17. Cohen S. M. Ellwein L. B. (1990b). Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: Biological modeling of the ED01 study. Toxicol Appl Pharmacol 104, 79–93.
18. Cohen S. M. Ellwein L. B. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Research 51, 6493–6505.
19. Cohen S. M. Ellwein L. B. (1993). Use of cell proliferation data in modeling urinary bladder carcinogenesis. Environ Health Perspect 101 (Suppl 5), 111–13.
20. Cohen S. M. Klaunig J. Meek M. E. Hill R. N. Pastoor T. Lehman-McKeeman L. Bucher J. Longfellow D. G. Seed J. Dellarco V. Fenner-Crisp P. Patton D. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci 78, 181–86.
21. Cohen S. M. Purtilo D. T. Ellwein L. B. (1991). Pivotal role of increased cell proliferation in human carcinogenesis. Mod Pathol 4, 371–82.
22. Dale K. M. Coleman C. I. Henyan N. N. Kluger J. White C. M. (2006). Statins and cancer risk: A meta-analysis. JAMA 295, 74–80.
23. Dietrich D. R. (1993). Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit Rev Toxicol 23, 77–109.
24. Dixon K. Kopras E. (2004). Genetic alterations and DNA repair in human carcinogenesis. Cancer Biology 14, 441–8.
25. Dragan Y. P. Bidlack W. R. Cohen S. M. Goldsworthy T. L. Hard G. C. Howard P. C. Riley R. T. Voss K. A. (2001). Implications of apoptosis for toxicity, carcinogenicity, and risk assessment: Fumonisin B1 as an example. Toxicol Sci 61, 6–17.
26. Drinkwater N. R. Hanigan M. H. Kemp C. J. (1990). Genetic and epigenetic promotion of murine hepatocarcinogenesis. Prog Clin Bio Res 331, 163–76.
27. Eldridge S. R. Tilbury L. F. Goldsworthy T. L. Butterworth B. E. (1990). Measurement of chemically induced cell proliferation in rodent liver and kidney: A comparison of 5-bromo-2’-deoxyuridine and [3H]thymidine administered by injection or osmotic pump. Carcinogenesis 11, 2245–51.
28. Ellinger-Ziegelbauer H. Gmuender H. Bandenburg A. Ahr H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res 637, 23–39.
29. Ellinger-Ziegelbauer H. Stuart B. Wahle B. Bomann W. Ahr H. J. (2004). Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci 77, 19–34.
30. Ellinger-Ziegelbauer H. Stuart B. Wahle B. Bomann W. Ahr H. J. (2005). Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 575, 61–84.
31. W.R., Farwell, R.E., Scranton, E.V., Lawler, R.A., Lew, M.T., Brophy, L.D., Fiore, J.M., Gaziano, The association between statins and cancer incidence in a veterans population, J Natl Cancer Inst, (2008), 100, 134-139
32. Fielden M. R. Brennan R. Gollub J. (2007). A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 99, 90–100.
33. Fielden M. R. Nie A. McMillian M. Elangbam C. S. Trela B. A. Yang Y. Dunn R. T. II Dragan Y. Fransson-Stehen R. Bogdanffy M. Adams S. P. Foster W. R. Chen S. J. Rossi P. Kasper P. Jacobson-Kram D. Tatsuoka K. S. Wier P. J. Gollub J. Halbert D. N. Roter A. Young J. K. Sina J. F. Marlowe J. Martus H. J. Aubrecht J. Olaharski A. J. Roome N. Nioi P. Pardo I. Snyder R. Perry R. Lord P. Mattes W. Car B. D. (2008). Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol Sci 103, 28–34.
34. Flamm W. G. Winbush J. S. (1984). Role of mathematical models in assessment of risk and in attempts to define management strategy. Fundam Appl Toxicol 4, S395–S401.
35. Gaikwad N. W. Yang L. Muti P. Meza J. L. Pruthi S. Ingle J. N. Rogan E. G. Cavalieri E. L. (2008). The molecular etiology of breast cancer: Evidence from biomarkers of risk. Int J Cancer 122, 1949–57.
36. Gold L. S. Manley N. B. Slone T. H. Rohrbach L. Garfinkel G. B. (2005). Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol Sci 85, 747–808.
37. Gold L. S. Slone T. H. Manley N. B. Bernstein L. (1991). Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect 93, 233–46.
38. Goodman Z. D. Terracciano L. M. (2007). Tumours and tumour-like lesions of the liver. In Pathology of the Liver (Burt A. D. Portmann B. Ferrell L. D., eds.), pp. 761–814. Churchill Livingston, Edinburgh, London.
39. Gratzner H. G. (1982). Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 218, 474–75.
40. Greaves P. Clothier B. Davies R. Higginson F. M. Edwards R. E. Dalton T. P. Nebert D. W. Smith A. G. (2005). Uroporphyria and hepatic carcinogenesis induced by polychlorinated biphenyls-iron interaction: Absence in the Cyp1a2 (-/-) knockout mouse. Biochem Biophys Res Commun 331, 147–52.
41. Greenfield R. E. Ellwein L. B. Cohen S. M. (1984). A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. Carcinogenesis 5, 437–45.
42. Gruber C. J. Tschugguel W. Schneeberger C. Huber J. C. (2002). Production and actions of estrogens. New England J Med 346, 340–52.
43. Hanawalt P. C. (1995). DNA repair comes of age. Mut Res 336, 101–13.
44. Harrison S. A. Bacon B. R. (2005). Relation of hemochromatosis with hepatocellular carcinoma: Epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 89, 391–409.
45. Haseman J. K. Hailey J. R. Morris R. W. (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol 26, 428–41.
46. Holsapple M. P. Pitot H. C. Cohen S. M. Boobis A. R. Klaunig J. E. Pastoor T. Dellarco V. L. Dragan Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89, 51–56.
47. International Agency for Research on Cancer (IARC) (1999a). Consensus report. IARC Scientific Publications 147, 1–32.
48. IARC (1999b). Hormonal contraception and post-menopausal hormonal therapy. In IARC Monographs, vol. 72, Cancers of the Liver and Gallbladder, pp. 168–80. IARC Press, Lyon, France.
49. IARC (2001). Phenobarbital and its sodium salt. In IARC Monographs, vol. 79, Some Thyrotropic Agents, pp. 161–288. IARC Press, Lyon, France.
50. Kirkland D. J. Aardema M. Banduhn N. Carmichael P. Fautz R. Meunier J. R. Pfuhler S. (2007). In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. Mutagenesis 22, 161–75.
51. Kirkland D. Aardema M. Henderson L. Muller L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: I. Sensitivity, specificity and relative predictivity. Mutat Res 584, 1–256.
52. Kirkland D. Aardema M. Muller L. Makoto H. (2006). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat Res 608, 29–42.
53. Kirkland D. J. Henderson L. Marzin D. Muller L. Parry J. M. Speit G. D. Tweats J. Williams G. M. (2005). Testing strategies in mutagenicity and genetic toxicology: An appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes. Mutat Res 588, 88–105.
54. Kirkland D. J. Muller L. (2000). Interpretation of the biological relevance of genotoxicity test results: The importance of thresholds. Mutat Res 464, 137–47.
55. Kirkland D. Pfuhler S. Tweats D. Aardema M. Corvi R. Darroudi F. Elhajouji A. Glatt H. Hastwell P. Hayashi M. Kasper P. Kirchner S. Lynch A. Marzin D. Maurici D. Meunier J. R. Muller L. Nohynek G. Parry J. Parry E. Thybaud V. Tice R. van Benthem J. Vanparys P. White P. (2007). How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat Res 628, 31–55.
56. Klaunig J. E. Babich M. A. Baetcke K. P. Cook J. C. Corton J. C. David R. M. DeLuca J. G. Lai D. Y. McKee R. H. Peters J. M. Roberts R. A. Fenner-Crisp P. A. (2003). PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit Rev Toxicol 33, 655–80.
57. Klaunig J. E. Kamendulis L. M. (2004). The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44, 239–67.
58. Knasmuller S. Mersch-Sundermann V. Kevekordes S. Darroudi F. Huber W. W. Hoelzl C. Bichler J. Majer B. J. (2004). Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198, 315–28.
59. Knudson A. G. Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci 68, 820–23.
60. Kowdley K. V. (2004). Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127, S79–86.
61. Lambert C. B. Spire C. Claude N. Guillouzo A. (2009). Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234, 345–60.
62. Lamminpaa A. Pukkala E. Teppo L. Neuvonen P. J. (2002). Cancer incidence among patients using antiepileptic drugs: A long-term follow-up of 28,000 patients. Eur J Clin Pharmacol 58, 137–41.
63. Lindahl T. Wood R. D. (1999). Quality control by DNA repair. Science 286, 1897–1904.
64. Loeb L. A. Harris C. C. (2008). Advances in chemical carcinogenesis: A historical review and prospective. Cancer Res 68, 6863–72.
65. Luebeck E. G. Moolgavkar S. H. (1996). Biologically based cancer modeling. Drug Chem Toxicol 19, 221–43.
66. MacDonald J. S. Gerson R. J. Kornbrust D. J. Kloss M. W. Prahalada S. Berry P. H. Alberts A. W. Bokelam D. L. (1988). Preclinical evaluation of lovastatin. Amer J Cardiol 62, 97–101.
67. MacDonald J. S. Halleck M. M. (2004). The toxicology of HMG-CoA reductase inhibitors: Prediction of human risk. Toxicol Pathol 32 (Suppl 2), 26–41.
68. McKinney J. D. Richard A. Waller C. Newman M. C. Gerberick F. (2000). The practice of structure activity relationships (SAR) in toxicology. Toxicol Sci 56, 8–17.
69. Meek M. E. Bucher J. R. Cohen S. M. Dellarco V. Hill R. N. Lehman-McKeeman L. D. Longfellow D. G. Pastoor T. Seed J. Patton D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33, 591–653.
70. Meza R. Jeon J. Moolgavkar S. H. Luebeck E. G. (2008). Age-specific incidence of cancer: Phases, transitions, and biological implications. Proc Natl Acad Sci 105, 16284–89.
71. Moggs J. G. Ashby J. Tinwell H. Lim F. L. Moore D. J. Kimber I. Orphanides G. (2004). The need to decide if all estrogens are intrinsically similar. Environ Health Perspect 112, 1137–42.
72. Moolgavkar S. H. Knudson A. G. Jr. (1981). Mutation and cancer: A model for human carcinogenesis. J Natl Cancer Inst 66, 1037–52.
73. Moore J. T. Moore L. B. Maglich J. M. Kliewer S. A. (2003). Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 1619, 235–38.
74. Nie A. Y. McMillian M. Parker J. B. Leone A. Bryant S. Yieh L. Bittner A. Nelson J. Carmen A. Wan J. Lord P. G. (2006). Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45, 914–33.
75. Pastoor T. Rose P. Lloyd S. Peffer R. Green T. (2005). Case study: Weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors. Toxicol Sci 86, 56–60.
76. Perdew G. H. (2008). Ah receptor binding to its cognate response element is required for dioxin-mediated toxicity. Toxicol Sci 106, 301–3.
77. Peto R. Gray R. Brantom P. Grasso P. (1991). Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrodiethylamine or N-nitrosodimethylamine. Cancer Res 51, 6452–69.
78. Phillips D. H. Farmer P. B. Beland F. A. Nath R. G. Poirier M. C. Reddy M. V. Turteltaub K. W. (2000). Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ Mol Mutagen 35, 222–33.
79. Powell C. J. (1994). Copper-overload causes cancer? The LEC rat: a model for human hepatitis, liver cancer, and much more. Hum Exp Toxicol 13, 910–12.
80. Powley M. W. Frederick C. B. Sistare F. D. DeGeorge J. J. (2009). Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem Res Toxicol 22, 257–62.
81. Preston-Martin S. Pike M. C. Ross R. K. Jones P. A. Henderson B. E. (1990). Increased cell division as a cause of human cancer. Cancer Research 50, 7415–21.
82. Ramaiah S. K. Rivera C. Arteel G. E. (2004). Early-phase alcoholic liver disease: An update on animal models, pathology, and pathogenesis. Int J Toxicol 23, 217–31.
83. Randerath K. Moorthy B. Mabon N. Sriram P. (1994). Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087–94.
84. Rhomberg L. R. Baetcke K. Blancato J. Bus J. Cohen S. Conolly R. Dixit R. Doe J. Ekelman K. Fenner-Crisp P. Harvey P. Hattis D. Jacobs A. Jacobson-Kram D. Lewandowski T. Liteplo R. Pelkonen O. Rice J. Somers D. Turturro A. West W. Olin S. (2007). Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection. Crit Rev Toxicol 37, 729–37.
85. Ross P. K. Woods C. G. Bradford B. U. Kosyk O. Gatti D. M. Cunningham M. L. Rusyn I. (2009). Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver. Toxicol Appl Pharmacol 235, 199–207.
86. Scholzen T. Gerdes J. (2000). The Ki-67 protein: From the known and the unknown. J Cell Physiol 182, 311–22.
87. Schwarz M. Appel K. E. (2005). Carcinogenic risks of dioxin: Mechanistic considerations. Regul Toxicol Pharmacol 43, 19–34.
88. Seed J. Carney E. W. Corley R. A. Crofton K. M. DeSesso J. M. Foster P. M. Kavlock R. Kimmel G. Klaunig J. Meek M. E. Preston R. J. Slikker W. Jr. Tabacova S. William G. M. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 35, 663–72.
89. Sheehan D. C. Hrapchak B. (1980). Theory and Practice of Histotechnology. 2nd ed. Mosby Company, St. Louis, MO.
90. Slater E. E. MacDonald J. S. (1988). Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 (Suppl 3), 72–82.
91. Slikker W. Jr. Andersen M. E. Bogdanffy M. S. Bus J. S. Cohen S. D. Conolly R. B. David R. M. Doerrer N. G. Dorman D. C. Gaylor D. W. Hattis D. Rogers J. M. Setzer R. W. Swenberg J. A. Wallace K. (2004). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol Appl Pharmacol 201, 226–94.
92. Snyder R. D. Green J. W. (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488, 151–69.
93. Sonich-Mullin C. Fielder R. Wiltse J. Baetcke K. Dempsey J. Fenner-Crisp P. Grant D. Hartley M. Knaap A. Kroese D. Mangelsdorf I. Meek E. Rice J. M. Younes M. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Reg Toxicol Pharmacol 34, 146–52.
94. Tennant R. W. Margolin B. H. Shelby M. D. Zeiger E. Haseman J. K. Spalding J. Caspary W. Resnick M. Stasiewicz S. Anderson B. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933–41.
95. Thomas R. S. Pluta L. Yang L. Halsey T. A. (2007). Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol Sci 97, 55–64.
96. Thybaud V. Aardema M. Clements J. Dearfield K. Galloway S. Hayashi M. Jacobson-Kram D. Kirkland D. MacGregor J. T. Marzin D. Ohyama W. Schuler M. Suzuki H. Zeiger E. (2007). Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing. Mutat Res 627, 41–58.
97. Tryndyak V. P. Muskhelishvili L. Kovalchuk O. Rodriguez-Juarez R. Montgomery B. Churchwell M. I. Ross S. A. Beland F. A. Pogribny I. P. (2006). Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: Implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 27, 1713–20.
98. Ueda A. Hamadeh H. K. Webb H. K. Yamamoto Y. Sueyoshi T. Afshari C. A. Lehmann J. M. Negishi M. (2002). Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 61, 1–6.
99. Van Oosterhout J. P. Van der Laan J. W. De Waal E. J. Olejniczak K. Hilgenfeld M. Schmidt V. Bass R. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 25, 6–17.
100. Walker N. J. Miller B. D. Kohn M. C. Lucier G. W. Tritscher A. M. (1998). Differences in kinetics of induction and reversibility of TCDD-induced changes in cell proliferation and CYP1A1 expression in female Sprague-Dawley rat liver. Carcinogenesis 19, 1427–35.
101. Ward J. M. Anver M. R. Haines D. C. Benveniste R. E. (1994). Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 145, 959–68.
102. Wei P. Zhang J. Egan-Hafley M. Liang S. Moore D. D. (2000). The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407, 920–23.
103. Weisburger J. H. Williams G. M. (1981). Carcinogen testing: Current problems and new approaches. Science 214, 401–7.
104. Whysner J. Ross P. M. Williams G. M. (1996). Phenobarbital mechanistic data and risk assessment: Enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 71, 153–91.
105. Yamada T. Uwagawa S. Okuno Y. Cohen S. M. Kaneko H. (2009). Case study: An evaluation of the human relevance of the synthetic pyrethroid metofluthrin-induced liver tumors in rats based on mode of action. Toxicol Sci 108, 59–68.
106. Yamamoto Y. Moore R. Goldsworthy T. L. Negishi M. Maronpot R. R. (2004). The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 64, 7197–7200.
107. Yang Q. Nagano T. Shah Y. Cheung C. Ito S. Gonzalez F. J. (2008). The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101, 132–39.
108. Yu M. W. Chang H. C. Chang S. C. Liaw Y. F. Lin S. M. Liu C. J. Lee S. D. Lin C. L. Chen P. J. Lin S. C. Chen C. J. (2003). Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 38, 1393–1400.
109. Zeiger E. (2004). History and rationale of genetic toxicity testing: An impersonal, and sometimes personal, view. Environ Mol Mutagen 44, 363–71.
110. Zeiger E. Ashby J. Bakale G. Enslein K. Klopman G. Rosenkranz H. S. (1996). Prediction of Salmonella mutagenicity. Mutagenesis 11, 471–84.